Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

24-02-2022 | ASCO GU 2022 | Conference coverage | Video

Mapping the impact of COVID-19 on genitourinary cancers

Chris Labaki takes us through his study evaluating temporal changes in the screening, diagnosis, and surgical treatment of genitourinary malignancies during the first year of the COVID-19 pandemic (5:02).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

25-03-2020 | COVID-19 | Podcast | Article

Managing patients with genitourinary cancers in the time of COVID-19

06-09-2021 | COVID-19 | News

Significant declines in cancer diagnoses during first year of COVID-19 pandemic

12-05-2021 | COVID-19 | News

COVID-19 leaves large cancer screening deficit in USA

26-07-2021 | Prostate cancer | News

Care of Black prostate cancer patients disproportionately affected during COVID-19
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits